# NT5DC2

## Overview
NT5DC2 is a gene that encodes the protein 5'-nucleotidase domain containing 2, which is a member of the NT5DC family involved in nucleotide metabolism. This protein functions primarily as a nucleotidase, catalyzing the dephosphorylation of nucleotides, a process essential for nucleotide recycling and maintaining cellular nucleotide balance. The protein is predominantly active in the cytoplasm and plays a significant role in cell proliferation and growth, impacting various cellular processes such as DNA replication and repair (Guo2019NT5DC2; Hu2021NT5DC2). NT5DC2 is implicated in several cancers, where it interacts with key proteins to influence tumor progression and patient prognosis, making it a potential therapeutic target (Schulze2022High; Li2020NT5DC2).

## Function
NT5DC2 (5'-nucleotidase domain containing 2) is a protein involved in nucleotide metabolism, primarily functioning as a nucleotidase that catalyzes the dephosphorylation of nucleotides. This activity is crucial for nucleotide recycling and maintaining cellular nucleotide balance, which is essential for various cellular processes such as DNA replication and repair. The protein is active in the cytoplasm, where it plays a significant role in cell proliferation and growth (Hu2021NT5DC2).

In healthy human cells, NT5DC2 is part of the NT5DC family, which includes other members like NT5DC1-4. Although the exact physiological roles of NT5DC2 are not fully understood, it is suggested to have potential metal ion binding and 5'-nucleotidase activity. These functions are important for maintaining the balance of nucleotides within the cell, thereby supporting normal cellular functions and organismal homeostasis (Guo2019NT5DC2).

The protein's involvement in nucleotide metabolism indicates its potential impact on cellular processes beyond purine-nucleotide metabolism, possibly affecting processes like ubiquitination and dephosphorylation, which are critical for cell cycle regulation and cellular signaling pathways (Li2020NT5DC2).

## Clinical Significance
NT5DC2 is implicated in several cancers, with its expression levels and interactions playing significant roles in disease progression and patient prognosis. In non-small cell lung cancer (NSCLC), particularly pulmonary adenocarcinoma, high NT5DC2 expression is associated with poor prognosis and reduced survival rates. This effect is potentially linked to its interaction with the tumor suppressor protein p53, where dysregulated p53 may exacerbate the malignancy associated with NT5DC2 overexpression (Schulze2022High). 

In hepatocellular carcinoma (HCC), NT5DC2 promotes tumor cell proliferation by stabilizing the epidermal growth factor receptor (EGFR), enhancing downstream signaling pathways crucial for cell proliferation. High NT5DC2 expression correlates with larger tumors and poorer survival outcomes, making it a potential therapeutic target (Li2020NT5DC2).

In colorectal carcinoma (CRC), NT5DC2 is upregulated and associated with poor survival. Its knockdown reduces cell proliferation, migration, invasion, and angiogenesis, primarily through the repression of VEGF signaling and the CCL2/CCR2 axis, which are crucial for tumor progression (Zhu2020NT5DC2).

NT5DC2 is also highly expressed in glioma stem-like cells, contributing to glioblastoma progression by upregulating Fyn signaling, which is associated with tumorigenicity (Guo2019NT5DC2).

## Interactions
NT5DC2 is involved in several protein-protein interactions that play significant roles in cancer progression. In glioma stem-like cells, NT5DC2 interacts with the Fyn protein, a member of the Src family of proto-oncogenes. This interaction is crucial for stabilizing Fyn protein levels by protecting it from degradation via the ubiquitin-proteasome pathway, as demonstrated by co-immunoprecipitation assays (Guo2019NT5DC2).

In hepatocellular carcinoma (HCC), NT5DC2 physically associates with the epidermal growth factor receptor (EGFR). This interaction stabilizes EGFR by reducing its ubiquitination, thereby preventing its degradation. The stabilization of EGFR by NT5DC2 enhances downstream signaling pathways, such as Ras-ERK and PI3K-AKT, which are critical for tumor cell proliferation (Li2020NT5DC2).

In diffuse large B-cell lymphoma (DLBC), NT5DC2 interacts with IGF2BP2, an RNA-binding protein. IGF2BP2 modulates the effects of NT5DC2 on cell proliferation and apoptosis, indicating a complex interaction that influences the p53 signaling pathway (Cui2022Decreased).

These interactions highlight NT5DC2's role in regulating key signaling pathways and its potential as a therapeutic target in various cancers.


## References


[1. (Schulze2022High) Arik Bernard Schulze, Anna Kuntze, Lars Henning Schmidt, Michael Mohr, Alessandro Marra, Ludger Hillejan, Christian Schulz, Dennis Görlich, Wolfgang Hartmann, Annalen Bleckmann, and Georg Evers. High expression of nt5dc2 is a negative prognostic marker in pulmonary adenocarcinoma. Cancers, 14(6):1395, March 2022. URL: http://dx.doi.org/10.3390/cancers14061395, doi:10.3390/cancers14061395. This article has 5 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/cancers14061395)

[2. (Guo2019NT5DC2) Saisai Guo, Haowen Ran, Dake Xiao, Haohao Huang, Lanjuan Mi, Xinzheng Wang, Lishu Chen, Da Li, Songyang Zhang, Qiuying Han, Tao Zhou, Ailing Li, and Jianghong Man. Nt5dc2 promotes tumorigenicity of glioma stem-like cells by upregulating fyn. Cancer Letters, 454:98–107, July 2019. URL: http://dx.doi.org/10.1016/j.canlet.2019.04.003, doi:10.1016/j.canlet.2019.04.003. This article has 29 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.canlet.2019.04.003)

[3. (Li2020NT5DC2) Kang-Shuai Li, Xiao-Dong Zhu, Hong-Da Liu, Shi-Zhe Zhang, Xiao-Long Li, Nan Xiao, Xue-Feng Liu, Bin Xu, Ming Lei, Yuan-Yuan Zhang, Wen-Kai Shi, Man-Qing Cao, Yun-Fei Xu, Zhao-You Tang, and Hui-Chuan Sun. Nt5dc2 promotes tumor cell proliferation by stabilizing egfr in hepatocellular carcinoma. Cell Death &amp; Disease, May 2020. URL: http://dx.doi.org/10.1038/s41419-020-2549-2, doi:10.1038/s41419-020-2549-2. This article has 35 citations.](https://doi.org/10.1038/s41419-020-2549-2)

[4. (Hu2021NT5DC2) Bowen Hu, Shijie Zhou, Xuefeng Hu, Hua Zhang, Xiaorong Lan, Mei Li, Yunbing Wang, and Qinsheng Hu. Nt5dc2 promotes leiomyosarcoma tumour cell growth via stabilizing unpalmitoylated tead4 and generating a positive feedback loop. Journal of Cellular and Molecular Medicine, 25(13):5976–5987, May 2021. URL: http://dx.doi.org/10.1111/jcmm.16409, doi:10.1111/jcmm.16409. This article has 14 citations and is from a peer-reviewed journal.](https://doi.org/10.1111/jcmm.16409)

[5. (Cui2022Decreased) Yuying Cui, Yu Wen, Chao Lv, Dongmei Zhao, Yu Yang, Hongbin Qiu, and Chennan Wang. Decreased rna‑binding protein igf2bp2 downregulates nt5dc2, which suppresses cell proliferation, and induces cell cycle arrest and apoptosis in diffuse large b‑cell lymphoma cells by regulating the p53 signaling pathway. Molecular Medicine Reports, July 2022. URL: http://dx.doi.org/10.3892/mmr.2022.12802, doi:10.3892/mmr.2022.12802. This article has 1 citations and is from a peer-reviewed journal.](https://doi.org/10.3892/mmr.2022.12802)

[6. (Zhu2020NT5DC2) Zhenyu Zhu, Qingsheng Hou, and Hongliang Guo. Nt5dc2 knockdown inhibits colorectal carcinoma progression by repressing metastasis, angiogenesis and tumor-associated macrophage recruitment: a mechanism involving vegf signaling. Experimental Cell Research, 397(1):112311, December 2020. URL: http://dx.doi.org/10.1016/j.yexcr.2020.112311, doi:10.1016/j.yexcr.2020.112311. This article has 21 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.yexcr.2020.112311)